html
Toronto, Ontario -- March 26, 2025 -- NewsGenie -- Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0"), a clinical-stage oncology company, announced the results of its Annual General and Special Meeting of Shareholders held on Wednesday, March 26, 2025.
A total of 40,294,667 common shares, representing 76.00% of Helix’s total issued and outstanding shares, were voted at the Meeting. Shareholders overwhelmingly approved all items of business.
The four director nominees, Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube, were re-elected as directors. The resolutions to appoint Clearhouse LLP as auditor, regarding asset transactions with Laevoroc Immunology AG and Laevoroc Chemotherapy AG, the equity draw-down subscription facility with GEM Yield Bahamas Limited, the consolidation of common shares, change of name to “Aconara Pharma Corp.”, and Equity Compensation Plan were also approved.
Helix BioPharma is focused on developing novel therapies for hard-to-treat cancers. Its lead candidate, Tumour Defence Breaker™ L-DOS47, is in clinical-stage development.
A report on all items of business voted at the Meeting will be filed on SEDAR+ at www.sedarplus.com.
Helix BioPharma Shareholders Approve Key Resolutions at Annual Meeting
Toronto, Ontario -- March 26, 2025 -- NewsGenie -- Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0"), a clinical-stage oncology company, announced the results of its Annual General and Special Meeting of Shareholders held on Wednesday, March 26, 2025.
A total of 40,294,667 common shares, representing 76.00% of Helix’s total issued and outstanding shares, were voted at the Meeting. Shareholders overwhelmingly approved all items of business.
The four director nominees, Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube, were re-elected as directors. The resolutions to appoint Clearhouse LLP as auditor, regarding asset transactions with Laevoroc Immunology AG and Laevoroc Chemotherapy AG, the equity draw-down subscription facility with GEM Yield Bahamas Limited, the consolidation of common shares, change of name to “Aconara Pharma Corp.”, and Equity Compensation Plan were also approved.
Helix BioPharma is focused on developing novel therapies for hard-to-treat cancers. Its lead candidate, Tumour Defence Breaker™ L-DOS47, is in clinical-stage development.
A report on all items of business voted at the Meeting will be filed on SEDAR+ at www.sedarplus.com.